42 Results for "

DARS

" in MedChemExpress (MCE) Product Catalog:
Products (42)

42 Results for "DARS" in MCE Product Catalog:

5
5 Cited Publications
Cat. No.: HY-10122
CAS No.: 160970-54-7
Purity:  99.82%
Synonyms: KAD 3213; KMD 3213
Research Areas:  

Endocrinology Cancer

Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .
5
5 Cited Publications
Cat. No.: HY-101299B
CAS No.: 137417-08-4
Purity:  98.89%
Synonyms: DAR-0100 hydrochloride
Target:  

Dopamine Receptor

Research Areas:  

Neurological Disease

Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC50 of 10 nM for D1 receptor. Dihydrexidine hydrochloride exhibits potent antiparkinsonian activity . Dihydrexidine hydrochloride can stimulate YAP phosphorylation .
2
2 Cited Publications
Cat. No.: HY-100554
CAS No.: 21102-95-4
Purity:  99.92%
Research Areas:  

Cardiovascular Disease

BMY 7378 is a selective antagonist of α1D-adrenoceptor 1D-AR). BMY 7378 binds to membranes expressing the cloned rat α1D-AR with a >100-fold higher affinity (Ki=2 nM) than binding to either the cloned rat α1A-AR (Ki=800 nM) or the hamster α1B-AR (Ki=600 nM). BMY 7378 is a 5-HT1A receptor partial agonist .
1
1 Cited Publications
Cat. No.: HY-P99542
CAS No.: 2254086-60-5
Synonyms: SAR-408701; HuMAb2-3-SPDB-DM4
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
Cat. No.: HY-164153
ADC Control Human IgG1-vcMMAE (DAR4, solution) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
Cat. No.: HY-164152A
ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
Cat. No.: HY-145448
CAS No.: 2722697-82-5
Purity:  99.93%
Research Areas:  

Cancer

MC-VC-PABC-amide-PEG1-CH2-CC-885 (compound I-1) is a neoDegrader-Linker conjugate, consists of the GSPT1 degrader/molecular glue CC-885 (HY-101488) and a linker. MC-VC-PABC-amide-PEG1-CH2-CC-885 can be conjugated to the antibody DAR3.7 that specifically targets CD56 to synthesize Antibody-Drug Conjugates (ADCs) .
Cat. No.: HY-164152

Research Areas:  

Cancer

ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
Cat. No.: HY-P99829
CAS No.: 1869937-48-3
Synonyms: PF-06647020; ABBV-647; h6M24-vc0101
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
Cat. No.: HY-101300
CAS No.: 40600-13-3
Purity:  99.65%
Synonyms: LD 3098 hydrochloride
Target:  

Adenosine Receptor

Research Areas:  

Neurological Disease

Cirazoline hydrochloride (LD 3098 hydrochloride) is a potent competitive full α1A-adrenergic receptor (α1A-AR) agonist (Ki=120 nM) and only a partial agonist at α1B-AR (Ki= 960 nM) and α1D-AR (Ki=660 nM) .
Cat. No.: HY-163099
CAS No.: 2928571-43-9
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
Cat. No.: HY-175888
CAS No.: 2921735-93-3
Synonyms: Mc-exo-EVC-Exatecan
Research Areas:  

Cancer

APL-1082 is a drug-Linker conjugate that can be used for ADC synthesis. APL-1082 contains Exatecan (HY-13631) and Linker (HY-175929). APL-1082 reduces aggregation and hydrophobicity in Trastuzumab (HY-P9907) ADCs, enables production of high-DAR (10) ADCs with homogeneity and defined physicochemical properties. APL-1082 forms a Trastuzumab ADC with enhanced stability, showing greater DAR retention over time. APL-1082 can be used for the research of gastric cancer .
Cat. No.: HY-136884
CAS No.: 339527-79-6
DAR-4M is a fluorescent indicator for nitric oxide (NO) based on the rhodamine chromophore (Ex/Em= 550/572 nm) .
Cat. No.: HY-101299A
CAS No.: 123039-93-0
Synonyms: DAR-0100
Target:  

Dopamine Receptor YAP

Research Areas:  

Neurological Disease

Dihydrexidine (DAR-0100) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist with an IC50 of 10 nM for D1 receptor. Dihydrexidine exhibits potent antiparkinsonian activity . Dihydrexidine can stimulate YAP phosphorylation .
Cat. No.: HY-RS03533
Research Areas:  

Others

DARS2 Human Pre-designed siRNA Set A contains three designed siRNAs for DARS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-156299
CAS No.: 1466546-35-9
Target:  

ADC Linkers

Research Areas:  

Cancer

NMS-P945 is an ADC linker that can be used in the synthesis of antibody-drug conjugates (ADCs). NMS-P945 is suitable for conjugation to mAbs with reproducible Drug Antibody Ratio (DAR) >3.5 .
Cat. No.: HY-175504
CAS No.: 932544-59-7
Target:  

Dopamine Receptor PERK

Research Areas:  

Neurological Disease

MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC50s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC50 > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC50 of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder .
Cat. No.: HY-RS20900
Research Areas:  

Others

Dars1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dars1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS03532
Research Areas:  

Others

DARS1 Human Pre-designed siRNA Set A contains three designed siRNAs for DARS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.: HY-RS27417
Research Areas:  

Others

Dars1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dars1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.